NIH-funded research R21 grant

Investigating genetic markers and antibody responses to predict chronic graft-versus-host disease

Official title: IGHG Genes (GM Allotypes) and Anti-CMV (UL70) Antibody Responses as Prognostic Markers for Chronic Graft-Versus-Host-Disease

Funded at Medical University of South Carolina · NIH-10809751 · Data updated 2026-11-12

This study is looking for clues in your genes and immune responses that might help doctors predict if you'll develop chronic graft-versus-host disease after a stem cell transplant, so if you join, you may have some tests done to help us learn more about this condition.

More Graft Versus Host Disease research and trials

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionMedical University of South Carolina
NIH-funded
Lab location1 site (Charleston, United States)
Project startApril 1, 2023
Project endJanuary 31, 2026
Funding year2024
Award (this year)$113,250
NIH project number5R21HL167662-02
Project IDNIH-10809751 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals who are undergoing or have undergone hematopoietic cell transplantation.

Less likely to help

Patients who have not received a hematopoietic cell transplant or those without a history of chronic graft-versus-host disease may not benefit from this research.

What this research studies

This research focuses on identifying genetic markers and antibody responses that could help predict the onset of chronic graft-versus-host disease (cGVHD) in patients who have undergone hematopoietic cell transplantation (HCT). By examining immunoglobulin GM genes and their relationship with cytomegalovirus (CMV) infections, the study aims to uncover biomarkers that can indicate which patients are at higher risk for developing cGVHD. The approach involves analyzing the interaction between GM alleles and antibody responses to CMV, which may influence the immune response and disease progression. Patients participating in this research may undergo genetic testing and antibody assessments to contribute to the understanding of cGVHD risk factors.

Why it matters

Potential benefit: If successful, this research could lead to improved early identification of patients at risk for chronic graft-versus-host disease, allowing for timely interventions.

How similar studies have gone: Other research has shown promise in identifying genetic markers for various autoimmune conditions, suggesting that this approach may yield valuable insights for cGVHD as well.

Where this research is happening

  • Medical University of South Carolina
    Charleston, United States
    Active

Researchers

  • Principal investigator: Pandey, Janardan P — Medical University of South Carolina
  • Study coordinator: Pandey, Janardan P

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.